Sionna Therapeutics director granted 17,340 options
Sionna Therapeutics director Joshua Resnick reported a grant of non-qualified stock options linked to 17,340 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sionna Therapeutics director Joshua Resnick reported a grant of non-qualified stock options linked to 17,340 shares of Common Stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036. They vest in full on the earlier of June 17, 2027 or the date of the next annual meeting, contingent on his continued board service. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising these options is turned over for the benefit of RA Capital’s funds and a managed account, and Resnick disclaims beneficial ownership of the options and underlying shares.
Insider Trade Summary
Grant/Award: 17,340 shares
Grant/Award
1 txn
Insider
Resnick Joshua
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 17,340 contracts (Direct)
Footnotes (2)
- F1. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
- F2. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Key Figures
Option grant size: 17,340 options
Exercise price: $36.73 per share
Expiration date: June 16, 2036
+2 more
5 metrics
Option grant size
17,340 options
Non-qualified stock option grant to director
Exercise price
$36.73 per share
Exercise price of non-qualified stock option
Expiration date
June 16, 2036
Option expiration for director grant
Vesting trigger date
Earlier of June 17, 2027 or next annual meeting
Full vesting condition subject to continued service
Post-transaction derivative holdings
17,340 options
Total options held after reported grant
Key Terms
Non-Qualified Stock Option, beneficial ownership, vesting, advisory fees, +1 more
5 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the stock option"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vesting financial
"This option vests in full upon the earlier of June 17, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
advisory fees financial
"which will offset advisory fees owed by the Fund"
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
separately managed account financial
"and a separately managed account (the "Account")"
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sionna Therapeutics (SION) disclose?
Sionna Therapeutics disclosed a grant of non-qualified stock options covering 17,340 shares of Common Stock to director Joshua Resnick. The options are part of his director compensation but are held for the benefit of RA Capital-managed investment vehicles.
What are the key terms of Joshua Resnick’s Sionna Therapeutics stock options?
The options cover 17,340 underlying shares at an exercise price of $36.73 per share and expire on June 16, 2036. They are non-qualified stock options, meaning they follow standard income tax treatment rather than incentive stock option rules.
When do Joshua Resnick’s Sionna Therapeutics options vest?
The options vest in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting. Vesting is conditional on Resnick’s continued service as a director through the applicable vesting date.
Who ultimately benefits from the Sionna Therapeutics options granted to Joshua Resnick?
Under an arrangement with RA Capital Management, any net cash or stock from exercising the options benefits RA Capital Healthcare Fund, related Nexus Funds, and a managed account. Resnick is obligated to turn over proceeds and disclaims beneficial ownership.
How many Sionna Therapeutics derivative securities does Joshua Resnick hold after this grant?
Following this transaction, Resnick is reported as holding 17,340 derivative securities in the form of non-qualified stock options. This figure reflects the full grant amount and represents his reported derivative holdings after the transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates